The RSV vaccine is currently recommended as a single dose for eligible individuals and is not given annually. For adults, especially those 75 and older or 50-74 with increased risk, only one dose is advised, with no current recommendation for revaccination. Infants born during or entering their first RSV season may receive a single dose of monoclonal antibody nirsevimab, with a possible second dose for the second season under clinical discretion. Pregnant people receive one dose during pregnancy between 32 and 36 weeks to protect the newborn. Protection from the RSV vaccine can last at least one to two years, and future recommendations on revaccination will depend on ongoing evaluations.
RSV Vaccine Frequency Summary:
- Adults 75+ and high-risk adults 50-74: single dose, no annual booster yet recommended.
- Infants: one dose of monoclonal antibody at the start of first RSV season; possible dose next season if ongoing risk.
- Pregnant people: one dose between 32-36 weeks of gestation each pregnancy.
- Protection lasts at least 1-2 years currently.
This means the vaccine is currently not given "often" like flu shots but rather once per appropriate season or life stage, with further updates pending as research continues.
